Nurse Practitioner Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Justin Snipes

Nurse Practitioner Morganton, NC Nurse Practitioner

NPI 1275799967 CMS profile 770599

219A Avery Ave, Morganton, NC 28655

Open in the dashboard

General payments

$8,716

518 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Justin Snipes of Morganton, NC is reported in the CMS Open Payments database as having received $8,716 across 518 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 96th percentile of Nurse Practitioner profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,679 84
2024 General $1,322 77
2023 General $1,825 105
2022 General $1,900 117
2021 General $1,990 135

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Justin Snipes
  • Nurse Practitioner median
  • Middle half of Nurse Practitioner
  • National median

In program year 2025, general payments to Justin Snipes were reported at $1,679. Among 41,044 Nurse Practitioner profiles paid that year, the median was $174 and the middle half received between $55 and $557.

Show as a table
Year Justin Snipes Nurse Practitioner median Middle half National median
2019 $0 $50 $22–$97 $163
2020 $0 $40 $16–$108 $114
2021 $1,990 $135 $40–$426 $132
2022 $1,900 $152 $48–$470 $149
2023 $1,825 $166 $54–$529 $160
2024 $1,322 $173 $55–$556 $164
2025 $1,679 $174 $55–$557 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Teva Pharmaceuticals USA, Inc. $1,419 79 payments
  2. Lilly USA, LLC $992 64 payments
  3. AbbVie, Inc. $936 57 payments
  4. Novo Nordisk Inc $916 62 payments
  5. Otsuka America Pharmaceutical, Inc. $330 18 payments
  6. AstraZeneca Pharmaceuticals LP $322 21 payments
  7. GlaxoSmithKline, LLC. $318 17 payments
  8. Salix Pharmaceuticals, a division of Bausch Health US, LLC $236 16 payments
  9. Bayer HealthCare Pharmaceuticals Inc. $230 14 payments
  10. Lundbeck LLC $222 11 payments
  11. Other $2,795 159 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $8,408 515 payments
  2. Education $308 3 payments
Products named General payments · program years 2021–2025
  1. RYBELSUS $728 50 payments
  2. Ozempic $676 48 payments
  3. AUSTEDO $543 40 payments
  4. VRAYLAR $517 30 payments
  5. Austedo XR $507 28 payments
  6. MOUNJARO $468 28 payments
  7. JARDIANCE $420 28 payments
  8. TRULICITY $364 26 payments
  9. TRELEGY ELLIPTA $318 17 payments
  10. ZEPBOUND $301 18 payments
  11. Other $6,446 371 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 234 drugs

Part D claims

16,802

Median for Nurse Practitioner: 389

Drug cost

$1,966,904

Median for Nurse Practitioner: $21,885

Branded share of claims

24%

Median for Nurse Practitioner: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Mounjaro Tirzepatide Brand 120 $140,757
Invega Sustenna Paliperidone Palmitate Brand 45 $134,292
Jardiance Empagliflozin Brand 119 $118,482
Eliquis Apixaban Brand 145 $97,250
Ozempic Semaglutide Brand 90 $96,394
Rexulti Brexpiprazole Brand 66 $92,561
Ingrezza Valbenazine Tosylate Brand 11 $87,071
Tresiba Flextouch U-100 Insulin Degludec Brand 123 $78,768
Januvia Sitagliptin Phosphate Brand 102 $78,597
Trulicity Dulaglutide Brand 65 $74,305

The 10 drugs with the highest cost, of 234 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 34 billing codes

Paid by Medicare

$27,851

Of which drugs: $474

Medicare patients

97

Average age 65

Services billed

606

42 women, 55 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Diabetes 56%
Arthritis 45%
Depression 34%
COPD 30%
Ischemic heart disease 25%
Chronic kidney disease 22%
Alzheimer's or dementia 15%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Vaccine for influenza for administration into muscle, 0.5 ml dosage 90656 Office 21 21 $460

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 33 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
Austedo XR
  • Teva Pharmaceuticals USA, Inc. $193
$193 — —
REXULTI
  • Otsuka America Pharmaceutical, Inc. $70
  • Lundbeck LLC $68
$138 66 —
RYBELSUS
  • Novo Nordisk Inc $102
$102 — —
VRAYLAR
  • AbbVie, Inc. $84
$84 25 —
JARDIANCE
  • Lilly USA, LLC $47
  • Boehringer Ingelheim Pharmaceuticals, Inc. $30
$78 119 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 33 with Patron

Records

518 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nurse Practitioner in North Carolina

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record